GelPOINT Path-assisted endoscopic removal of colorectal polyps
Official title: GelPOINT® Path-Assisted Endoscopic Submucosal Dissection for Colorectal Polyps: A Feasibility and Safety Study
Run by Baylor College of Medicine · NCT07723937 · Data updated 2026-11-12
This study tests whether using the GelPOINT Path access platform during endoscopic submucosal dissection can safely help remove colorectal polyps in adults.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Baylor College of Medicine Academic / other |
| Locations | 1 site (Houston, Texas) |
| Status | Recruiting |
| Started | May 19, 2026 |
| Main results expected | March 25, 2027 |
| Study ends | April 30, 2027 |
| Registry record updated | July 23, 2026 |
| Trial ID | NCT07723937 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 or older with eligible colorectal polyps located in the transverse/descending colon, rectosigmoid, or rectum and referred for ESD, including larger or scarred lesions.
✕Probably not a fit
Patients whose polyps are not technically challenging or whose anatomy precludes GelPOINT Path use may not experience additional benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, single-center observational study evaluating the feasibility and safety of GelPOINT Path-assisted endoscopic submucosal dissection (ESD) for colorectal polyps. Adult patients undergoing ESD for eligible lesions will be enrolled and treated by experienced endoscopists as part of routine care. Outcomes will include technical feasibility, procedural performance, resection results, and any procedure-related adverse events, with follow-up around 4 weeks for delayed events. Data will be collected prospectively using standardized forms to assess whether the platform improves access, visualization, and stability during distal colon and rectal procedures without altering standard management. Approximately 30 patients are planned for enrollment at Baylor College of Medicine in Houston, TX.
Why it matters
Potential benefit: If successful, the approach could make complex colorectal polyp removal safer and more efficient for patients undergoing ESD.
How similar studies have gone: Prior TAMIS-use of GelPOINT Path has shown benefits in access and visualization, but its application to colorectal ESD is exploratory.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 18 years or older. * Able and willing to provide written informed consent. * Colorectal polyps located in the transverse colon, descending colon, rectosigmoid colon, or rectum (rectal lesions located at least 2 cm from the anal verge). * Referred for endoscopic submucosal dissection (ESD) of colorectal neoplastic lesions meeting at least one of the following criteria: * Lesions with prior resection or scarring proximal to the sigmoid colon. * Granular lateral spreading tumors (GLST) \>30 mm. * Non-granular lateral spreading tumors (NGLST) \>20 mm. * Lesions with suspected submucosal invasion, including Paris classification IIa+IIc lesions or lesions with a positive non-lifting sign Exclusion Criteria: * Younger than 18 years of age. * Unable or unwilling to provide informed consent. * Pregnant. * Pedunculated lesions (Paris classification Ip or Isp). * Lesions involving the appendix or ileocecal valve
Where it's running
-
Baylor College of Medicine
Houston, Texas, United States Recruiting
Study contacts
- Principal investigator: Tara Keihanian, MD — Baylor College of Medicine
- Study coordinator: Tara Keihanian, MD
- Email: Tara.Keihanian@bcm.edu
- Phone: 631-800-4142
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Liquid biopsy and machine learning to detect early colorectal cancer, advanced adenomas, Lynch-related cancers, and residual disease
This project will test a blood-based liquid biopsy that uses microRNA signals and machine learning to detect colorectal cancer, advanced adenomas, Lynch-associated cancers, and molecular residual disease in people who have a colonoscopy.
-
Bi‑manual EndoTEM system to remove polyps from the rectum and lower sigmoid colon
This will test whether the EndoTEM system can safely and completely remove large rectal and distal sigmoid polyps in adults.
-
Using deep learning and Raman spectroscopy for early cancer diagnosis
This study is trying to see if a new deep learning tool using blood samples can help spot early signs of different types of cancer, like colorectal and gastric cancers, in both healthy people and those already diagnosed.
-
Testing rectal mucus for colorectal cancer detection
This study is testing a new way to use rectal mucus samples to see if it can help find colorectal cancer and important polyps in patients who need urgent cancer checks.
-
Evaluating adenoma recurrence after specific endoscopic procedures
This study is testing which of two different techniques for removing large colon polyps helps prevent the return of adenomas in adults who are having a colonoscopy.
-
AI-assisted colonoscopy for polyp detection
This study tests whether using artificial intelligence during colonoscopy can help doctors find more polyps in patients getting screened or followed up for colon health.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.